证券代码：002900 证券简称：哈三联 公告编号：2019-049 哈尔滨三联药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"2019 年黑龙江省上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参与公司本次 投资者集体接待日活动，时间为 2019 年 6 月 19 日（周三）14:00 至 16:30。 届时公司销售副总经理梁延飞先生、财务副总经理兼财务总监韩冰女士、 董事长助理兼证券事务代表沈晓溪女士将通过网络在线问答互动的形式，与投资 者就公司治理、发展经营情况和可持续发展等投资者关注的问题进行交流。 欢迎广大投资者积极参与。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2019 年 6 月 1 ...

哈尔滨三联药业股份有限公司 2019 年第一季度报告全文 哈尔滨三联药业股份有限公司 2019 年第一季度报告 2019 年 04 月 1 哈尔滨三联药业股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证季度报告中财务报表的真实、准确、完整。 2 哈尔滨三联药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 500,698,083.97 | 472,420,679.46 | 5.99% | | 归属于上市公司股东的净利润（元） | 53,536,933.55 | 62,08 ...

Dividend Distribution - The company plans to distribute a cash dividend of 6.50 RMB per 10 shares (including tax) to all shareholders[4] - In 2018, the cash dividend amounted to 202,987,481.45 CNY, representing 98.63% of the net profit attributable to ordinary shareholders[115] - The proposed cash dividend for the current period is 6.5 CNY per 10 shares, with a total cash dividend of 202,987,481.45 CNY based on 312,288,433 shares[116] - The total distributable profit for the current period is 462,981,542.71 CNY, with the cash dividend accounting for 100% of the profit distribution[116] - The 2017 profit distribution plan involved a cash dividend of 5 CNY per 10 shares, totaling 105,533,350 CNY, and a capital reserve increase of 5 shares for every 10 shares held, raising total shares to 316,600,050[114] Financial Performance - The company's operating revenue for 2018 was ¥2,172,516,438.89, representing an increase of 89.11% compared to ¥1,148,830,317.73 in 2017[17] - The net profit attributable to shareholders for 2018 was ¥205,813,379.52, a 13.66% increase from ¥181,075,538.25 in 2017[17] - The net cash flow from operating activities increased by 30.88% to ¥292,457,733.07 in 2018, compared to ¥223,458,300.27 in 2017[17] - The total assets at the end of 2018 were ¥2,513,555,386.13, reflecting a 15.10% increase from ¥2,183,746,388.06 at the end of 2017[17] - The net assets attributable to shareholders at the end of 2018 were ¥1,947,459,154.39, up 6.13% from ¥1,834,946,594.59 at the end of 2017[17] Risk Management - The company is exposed to various risks, including industry policy changes, new drug development risks, and fluctuations in raw material prices[4] - The company has established a comprehensive risk management framework to address potential investment risks[4] - The company faces risks from industry policy changes, including intensified competition due to drug price reductions and procurement policies[102] - The company anticipates challenges from raw material price fluctuations and supply risks, necessitating proactive procurement strategies[105] Research and Development - The company reported a significant focus on new drug development, which includes both innovative and improved drugs[9] - The company has invested significantly in drug research and development, facing potential risks related to regulatory changes and funding requirements[103] - The company has developed a polypropylene ampoule injection, which is currently the only packaging form of its kind in China, enhancing its competitive edge[36] - The company has invested in five major R&D platforms, focusing on innovative differentiated strategies to drive continuous development[36] - The company is committed to strengthening its research and development efforts, focusing on key projects such as polypropylene ampoules and injectable consistency evaluations[99] Market Expansion - The company has a robust strategy for market expansion, leveraging its subsidiaries to penetrate new markets[8] - The company achieved an annual revenue of CNY 2.173 billion, representing a significant growth of 89.11% compared to the previous year[42] - The sales network has been strengthened, with a 35% increase in the number of distributors compared to the previous year, enhancing market coverage[39] - The company aims to enhance its competitive edge in the infusion market in Heilongjiang Province while expanding sales to new provinces[98] Corporate Governance - The company emphasizes the importance of maintaining accurate and complete financial reporting, ensuring accountability among its executives[3] - The management team has pledged to adhere strictly to corporate governance standards and legal regulations in exercising shareholder rights[124] - The company has established strict compliance measures for major shareholders to ensure transparency and accountability in shareholding practices[121] - The management team, including key executives, has committed to not engage in any actions that would harm the company's interests or its shareholders[124] Shareholder Relations - The controlling shareholder, Qin Jianfei, committed to stabilizing the stock price by potentially increasing shareholdings if necessary[119] - The company has implemented strict measures to ensure compliance with stock price stabilization plans approved by the shareholders' meeting[119] - The company will ensure that any share transfers by executives comply with regulatory requirements and internal policies[120] - The company has established a framework for share repurchase plans to support stock price stability[119] Social Responsibility - The company actively participates in social responsibility initiatives, including the establishment of the Heilongjiang Province Hasi Lian Charity Foundation, contributing CNY 2,000,000 annually for support activities[160] - The company provided a total of 19.7 million yuan for poverty alleviation efforts, helping 2 registered impoverished individuals to escape poverty[162] - The company has committed to ongoing poverty alleviation initiatives, including support for impoverished students and assistance for struggling employees[164] - The company has allocated 0.6 million yuan for industry development poverty alleviation projects, although no projects were reported[162] Compliance and Legal Matters - The company has not experienced any major accounting errors requiring retrospective restatement during the reporting period[131] - There were no significant legal disputes or arbitration matters affecting the company during the reporting period[135] - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[138] - The company reported no penalties or rectification situations during the reporting period[136]

哈尔滨三联药业股份有限公司 2018 年第三季度报告正文 1 所有董事均已出席了审议本次季报的董事会会议。 哈尔滨三联药业股份有限公司 2018 年第三季度报告正文 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证季度报告中财务报表的真实、准确、完整。 证券代码：002900 证券简称：哈三联 公告编号：2018-061 2 哈尔滨三联药业股份有限公司 2018 年第三季度报告正文 哈尔滨三联药业股份有限公司 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 2018 年第三季度报告正文 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -3,548,740.86 | 主要系报告期内根据《哈尔滨市 | | | | 2018 年"治霾卫蓝"工作实施方 | | | | 案》，处置锅炉及配套设施所致。 | | 计入当期损 ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2018, representing a year-on-year increase of 15% compared to RMB 1.04 billion in the same period of 2017[13]. - The net profit attributable to shareholders for the first half of 2018 was RMB 200 million, up 20% from RMB 166.67 million in the first half of 2017[13]. - The company's operating revenue for the reporting period reached ¥995,440,227.20, representing a 160.62% increase compared to ¥381,950,356.86 in the same period last year[19]. - Net profit attributable to shareholders was ¥144,432,383.13, up 78.14% from ¥81,078,797.39 year-on-year[19]. - The net cash flow from operating activities surged by 482.55% to ¥188,029,396.08, compared to ¥32,276,974.94 in the previous year[19]. - Basic earnings per share increased by 35.29% to ¥0.46, compared to ¥0.34 in the same period last year[19]. - The company achieved a revenue of CNY 995.44 million in the reporting period, representing a year-on-year increase of 160.62% compared to CNY 381.95 million in the same period last year[39][43]. - The net profit attributable to shareholders was CNY 144.43 million, reflecting strong financial performance amid a challenging regulatory environment[39]. Market Expansion and Product Development - The company plans to invest in new drug research and development, focusing on innovative therapies and expanding its product pipeline[5]. - The company aims to expand its market presence through strategic partnerships and potential acquisitions in the pharmaceutical sector[5]. - User data indicates a growing customer base, with an increase in prescriptions filled by 10% in the first half of 2018 compared to the previous year[13]. - The company is enhancing its production capabilities to meet the increasing demand for its products, particularly in the large-volume injection segment[11]. - Future guidance suggests a revenue growth target of 10-15% for the full year of 2018, driven by new product launches and market expansion efforts[13]. - The company has a dedicated R&D team of 226 professionals, accounting for 14.38% of total employees, focusing on innovative drug development[33]. - The company aims to drive sustainable development through market-oriented R&D and continuous innovation[33]. - The company plans to launch two new products in Q3 2018, targeting a market share increase of 5%[94]. - The company plans to launch three new products in the next quarter, targeting a market expansion of 10% in the pharmaceutical sector[96]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[96]. Financial Guidance and Risks - The company is facing risks related to industry policy changes, new drug development, and fluctuations in investment returns, which may impact future performance[5]. - The company expects a net profit attributable to shareholders for the first nine months of 2018 to range between ¥14 million and ¥19 million, representing a year-on-year increase of 11.11% to 50.80%[77]. - The main reasons for the expected profit increase include government subsidies and enhanced market development efforts, despite uncertainties from stock price fluctuations[77]. - The company is facing risks from industry policy changes, including stricter regulations and increased competition, and plans to adjust strategies accordingly to maintain competitive advantages[78]. - The company anticipates continued pressure on drug prices due to national healthcare reforms and plans to optimize product structure and expand production to mitigate this risk[83]. Compliance and Governance - No cash dividends or stock bonuses will be distributed to shareholders for the reporting period[6]. - The company is committed to maintaining compliance with GMP standards and improving operational efficiency to mitigate risks associated with production[11]. - The company has not reported any related party transactions that violate regulations[98]. - The company has established measures to prevent improper influence through its controlling shareholder status[98]. - The company has made commitments to ensure compliance with labor laws and social insurance regulations[98]. - The company guarantees to compensate for any economic losses due to tax issues related to foreign investment tax incentives[98]. - The company has committed to not engage in any business activities that compete with its main business[97]. Social Responsibility and Environmental Compliance - The company has established the Heilongjiang Province Hasi Lian Charity Foundation, committing 2 million yuan annually to support underprivileged students and provide medical assistance to patients with severe illnesses[125]. - The company actively participates in the "Hundred Enterprises Help Hundred Villages" initiative, with its chairman serving as an honorary village chief to promote targeted poverty alleviation efforts[124]. - The company has reported no significant environmental pollution issues and complies with pollution discharge standards[119]. - The company implemented dual-alkali methods for SO2 removal and low-NOx combustion methods for NOx removal in its boiler emissions, significantly reducing atmospheric pollutants[122]. - The company has set up wastewater treatment facilities that meet the discharge standards before releasing effluents to the local treatment plant, ensuring compliance with environmental regulations[122]. Shareholder Engagement and Capital Management - The company held two shareholder meetings during the reporting period, with participation rates of 52.25% and 65.38% respectively, indicating active investor engagement[87]. - The controlling shareholder has committed to not transferring or entrusting shares for 36 months post-IPO, with strict adherence to this commitment[89]. - The lock-up period for shares held by major shareholders has been extended by 6 months, ensuring compliance with the original commitments[90]. - The company has implemented measures to stabilize stock prices post-IPO, with commitments to disclose any failures to meet these obligations[90]. - The company distributed a cash dividend of 5.00 RMB per 10 shares and increased its total share capital from 211,066,700 shares to 316,600,050 shares[134]. Audit and Financial Reporting - The semi-annual financial report for Harbin Sanlian Pharmaceutical Co., Ltd. has not been audited[99]. - There were no bankruptcy reorganization matters during the reporting period[101]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[194]. - The company’s accounting policies include provisions for bad debts and inventory valuation methods[192]. - The company has not reported any overdue commitments as of the end of the reporting period[89].

Financial Performance - The company's operating revenue for Q1 2018 was ¥472,420,679.46, representing a 177.24% increase compared to ¥170,398,692.18 in the same period last year[8] - The net profit attributable to shareholders for Q1 2018 was ¥62,080,204.70, up 151.87% from ¥24,647,471.35 year-on-year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,536,322.01, reflecting a 23.32% increase from ¥22,328,950.59 in the previous year[8] - Basic earnings per share for Q1 2018 were ¥0.29, an increase of 81.25% from ¥0.16 in the previous year[8] - The weighted average return on net assets for Q1 2018 was 3.33%, an increase of 0.33% compared to 3.00% in the previous year[8] Cash Flow and Assets - The net cash flow from operating activities for Q1 2018 was ¥70,026,726.62, a significant improvement of 531.02% compared to -¥16,246,679.05 in the same period last year[8] - Total assets at the end of Q1 2018 were ¥2,307,931,848.97, a 5.69% increase from ¥2,183,746,388.06 at the end of the previous year[8] - The net assets attributable to shareholders at the end of Q1 2018 were ¥1,897,026,799.29, up 3.38% from ¥1,834,946,594.59 at the end of the previous year[8] - Cash flow from operating activities increased to ¥503,467,073.54, up 222.94% from ¥155,899,115.49, attributed to higher operating revenue[16] Expenses and Investments - Sales expenses surged to ¥310,780,902.47, reflecting a 958.63% increase from ¥29,356,872.68, primarily due to intensified academic promotion and sales terminal development[16] - Investment payments rose significantly to ¥463,199,734.41, a 7620.00% increase from ¥6,000,000.00, mainly for purchasing financial products and equity investments[17] Government Support and Other Income - The company received government subsidies amounting to ¥7,590,053.30 during the reporting period, primarily related to local government support[9] - The company reported a substantial increase in other income to ¥7,590,053.30, up 128.04% from ¥3,328,443.38, mainly from government subsidies[16] Forecast and Liabilities - The company reported a net profit forecast for the first half of 2018, estimating a growth range of 23.34% to 60.34%, translating to a net profit between ¥10,000,000 and ¥13,000,000[20] - The company recorded a deferred tax liability of ¥4,492,557.31, reflecting a dramatic increase of 187,096.92% due to fair value changes[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,436[12] - The company has no reported violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[23][24]

Dividend Distribution - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares to all shareholders, based on a total of 211,066,700 shares[5]. - The cash dividend distribution for 2016 was 126,640,000 yuan, which represented 72.29% of the net profit attributable to ordinary shareholders[117]. - The cash dividend for 2015 was 94,980,000 yuan, accounting for 57.11% of the net profit attributable to ordinary shareholders[117]. - The total distributable profit for the year 2017 was 372,366,533.43 yuan, with cash dividends representing 100% of the profit distribution[117]. - The cash dividend payout ratio for 2017 is 58.28% of the net profit attributable to ordinary shareholders[116]. - The company has maintained a consistent cash dividend policy over the past three years, with no proposals for stock dividends[114]. - The cash dividend for 2016 was distributed based on a total share capital of 158,300,000 shares, with a payout of 3 yuan for every 10 shares in the first half and 5 yuan in the second half[114]. - The company has not made any adjustments to its cash dividend policy during the reporting period, ensuring compliance and transparency[113]. Financial Performance - The company's operating revenue for 2017 was ¥1,148,830,317.73, representing a 50.99% increase compared to ¥760,872,100.78 in 2016[6]. - The net profit attributable to shareholders for 2017 was ¥181,075,538.25, a 3.36% increase from ¥175,182,785.55 in 2016[6]. - The net profit after deducting non-recurring gains and losses was ¥163,654,963.79, showing a decrease of 1.38% from ¥165,946,621.78 in 2016[6]. - The total assets at the end of 2017 reached ¥2,183,746,388.06, an increase of 87.26% from ¥1,166,188,074.98 at the end of 2016[18]. - The net assets attributable to shareholders increased by 127.05% to ¥1,834,946,594.59 at the end of 2017 from ¥808,173,769.27 at the end of 2016[18]. - The basic earnings per share for 2017 was ¥1.06, a decrease of 4.50% from ¥1.11 in 2016[18]. - The weighted average return on equity for 2017 was 16.78%, down from 22.69% in 2016[18]. - The company reported a net cash flow from operating activities of ¥223,458,300.27, a decrease of 3.34% from ¥231,183,499.98 in 2016[6]. Risk Factors - The company has faced risks including industry policy changes, new drug development risks, and bidding price reductions, which are detailed in the report[5]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements in the report[5]. - The company faces risks from industry policy changes, new drug development challenges, and potential delays in fundraising project implementations, which it aims to mitigate through strategic adjustments and enhanced marketing efforts[103][104][106]. Research and Development - The company invested CNY 69.35 million in R&D, accounting for 6.04% of total annual revenue, focusing on innovative drug development and enhancing internal growth momentum[46]. - The company completed the clinical approval for 24 product specifications, including the raw material and formulation of Lurasidone Hydrochloride, marking significant progress in its R&D efforts[44]. - The company established a collaborative research platform with several prestigious institutions, including Shenyang Pharmaceutical University and Heilongjiang University of Chinese Medicine, to enhance its drug development capabilities[46]. - The company is focusing on the secondary development of existing products, with initial success in the development of packaging for its flagship product, Olasacetam injection[35]. Market Expansion and Strategy - The company plans to continue expanding its market presence and product offerings, leveraging the funds raised from the IPO for strategic investments and development[82]. - The company aims to become a leading innovative pharmaceutical enterprise by focusing on differentiated innovation, intelligent production, international standards, and refined market strategies over the next 5-10 years[94]. - The company will implement a strategy of "independent R&D + external integration" to upgrade its product line and optimize its profit structure[98]. - A comprehensive upgrade of the marketing system is planned for 2018, aiming to enhance market control and establish a new marketing model[99]. Corporate Governance and Compliance - The company has not reported any changes in its main business since its listing[16]. - The company has not undergone any changes in its controlling shareholders since its establishment[16]. - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[118]. - The company reported a commitment to stabilize stock prices and will implement measures as approved by the shareholders' meeting[119]. - The management team is committed to maintaining transparency and accountability in their operations[124]. Environmental Responsibility - The company emphasizes environmental protection and resource conservation, implementing measures to reduce pollutant emissions[160]. - The company reported a total emission of 75,696 kg of sulfur dioxide, which complies with national standards[164]. - The company reported a total emission of 114,690.93 kg of smoke, which also meets national standards[165]. - The company has established an environmental self-monitoring plan to monitor pollutant emissions[170]. Shareholder Information - The largest shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 82,470,000 shares[181]. - The company has 41,420 shareholders at the end of the reporting period, a significant increase from 38,436 previously[181]. - Major shareholders, including Qin Jianfei, have committed to not transferring or entrusting their shares for twelve months post-IPO[120]. - The company will not distribute cash dividends to directors and senior management during the stock price stabilization period[120].

Financial Performance - Operating revenue for the period was CNY 285,800,075.95, a 55.55% increase year-on-year[8] - Net profit attributable to shareholders was CNY 44,919,211.58, up 12.23% compared to the same period last year[8] - Net profit after deducting non-recurring gains and losses was CNY 44,083,900.02, an increase of 16.98% year-on-year[8] - Cash flow from operating activities was CNY 76,964,091.86, a 44.71% increase compared to the same period last year[8] - The company expects a net profit attributable to shareholders for 2017 to range between ¥175,182,800 and ¥192,701,100, reflecting a growth of 0.00% to 10.00% compared to the previous year[20] Assets and Shareholder Equity - Total assets increased by 87.22% to CNY 2,183,304,575.56 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 120.23% to CNY 1,779,869,065.31[8] - The company's cash and cash equivalents increased by 715.73% to ¥1,051,055,237.20 due to the issuance of new shares during the reporting period[16] - The company's capital reserve increased by 296.72% to ¥1,165,983,593.01, primarily due to the issuance of new shares[16] - The total number of shareholders at the end of the reporting period was 100,443[12] Expenses and Costs - Sales expenses surged by 86.89% to ¥178,296,349.53, driven by increased market promotion costs[17] - The company reported a 43.13% increase in tax payments to ¥139,561,716.95, attributed to higher operating income during the reporting period[17] Receivables and Inventory - Accounts receivable rose by 64.61% to ¥125,848,704.66, influenced by the "two-invoice system" policy in the pharmaceutical industry[16] - The company's inventory increased by 60.07% to ¥142,686,449.17 due to stockpiling for production line upgrades[16] - The company's other receivables increased by 151.02% to ¥1,041,257.81, mainly due to an increase in bid guarantee deposits[16] Non-Recurring Gains - The company reported non-recurring gains of CNY 6,581,105.93, primarily from the sale of equity in Zhongfu Pharmaceutical[10] - The company reported a 100.00% increase in investment income to ¥30,478,650.42 from the disposal of shares in Zhongfu Pharmaceutical[17] - The company received cash from investment recovery amounting to ¥34,552,320.00 from the disposal of shares in Zhongfu Pharmaceutical[17] Earnings and Returns - Basic earnings per share decreased by 16.00% to CNY 0.21[8] - The weighted average return on net assets was 5.93%, down 6.65% from the previous year[8]